title: Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
abstract: OBJECTIVE
  Oral mucositis (OM) is an unresolved problem among patients treated with a high-dose therapy supported by hematopoietic stem cell transplantation (HSCT). We tested the ability of supersaturated calcium phosphate mouth rinse (Caphosol) to ameliorate oral mucosal injury induced by a conditioning regimen.
  
  
  METHODS
  Thirty-two patients with hematologic malignancies were treated with Caphosol to prevent OM during HSCT procedures. The conditioning regimens for 16 patients were BGNU 300 mg/m2, day 6; ARA-C 200 mg/m2 daily, days 5, 4, 3, 2; VP-16 200 mg/m2 daily, days 5, 4, 3, 2; L-PAM 140 mg/m2, day 1 (BEAM) and for 16 patients, MEL 200 (non-Hodgkin's lymphoma). A control group was composed of 24 consecutive patients, who had been treated with HSCT before Caphosol was available. The source of the graft was autologous peripheral blood.
  
  
  RESULTS
  Among patients treated with Caphosol no one had to receive total parenteral nutrition. Among the BEAM group no one experienced III to IV degree OM compared with 40% of the control group. The median OM duration was 2.25 days versus controls of 8.6, (P<.001); only one patient received opioids versus 100% of controls. In the MEL 200 group, 93.7% of patients developed 0 to II degree OM vs 94% of the control group (P=.74) with median duration of 1, 73 days versus 2.42 for the controls (P=.73). In both control and Caphosol cohorts one patient received opioids.
  
  
  CONCLUSIONS
  Caphosol may reduce the incidence, severity, and duration of oral mucositis and decrease the number of days with painkillers among patients treated with a BEAM but not a Mel 200 regimen.
authors: BMT Unit, Department of Oncology, Central Hospital, Military Institute of Medicine, Warsaw, Poland. anna.wasko@autograf.pl
authors: A
authors: A
authors: Waśko-Grabowska
authors: P
authors: P
authors: Rzepecki
authors: S
authors: S
authors: Oborska
authors: J
authors: J
authors: Barzał
authors: K
authors: K
authors: Gawroński
authors: B
authors: B
authors: Młot
authors: C
authors: C
authors: Szczylik
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002130:Calcium Phosphates / Q000008:administration & dosage*; D002330:Carmustine / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D008558:Melphalan / Q000009:adverse effects*; D008875:Middle Aged; D009067:Mouthwashes / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000628:therapy; D013280:Stomatitis / Q000517:prevention & control*; D019172:Transplantation Conditioning / Q000009:adverse effects; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D002130:Calcium Phosphates; D009067:Mouthwashes; D003561:Cytarabine; D005047:Etoposide; C020243:calcium phosphate; D008558:Melphalan; D002330:Carmustine